EMA's Revised Pediatric Class Waiver List Comes Into Effect July 28
Executive Summary
Marketing authorization applications for medicines that are no longer subject to a class waiver as per the revised list will need a pediatric investigation plan.
You may also be interested in...
EMA revokes eight class waivers for PIPs to 'encourage' development of drugs for children
The European Medicines Agency has revoked eight class waivers for pediatric investigation plans (PIPs) in a bid to encourage companies to develop more new medicines for use in children. The agency has also confirmed nine class waivers on its current list of class waivers, which means there continues to be no requirement for PIPs for medicines for treating these diseases, and it has updated 15 class waivers on the list1-5.
EMA makes 'extensive changes' to list of class waivers for pediatric investigation plans
Big changes are afoot at the European Medicines Agency regarding the regulation of pediatric medicines.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.